Skip to main content

Table 1 Clinical characteristics

From: Decreased level of serum carnitine might lead to arteriosclerosis progression via the accumulation of advanced glycation end products in maintenance hemodialysis patients

Number of patients (male/female) (n)

116 (65/51)

Age (years)

62 ± 13

Body mass index (kg/m2)

21.3 ± 3.3

Type 2 diabetes mellitus (+/−)(n)

48/68

Treatment (%)

 ARB/ACE inhibitor

31.0

 Iron therapy

37.1

Systolic blood pressure (mmHg)

149 ± 24

Diastolic blood pressure (mmHg)

88 ± 16

Heart rate (/min)

77 ± 12

Duration of hemodialysis (years)

7.6 ± .2

Kt/V (range)

1.10 ± 0.31

Hemoglobin A1c (%)

5.4 ± 0.7

Glycated albumin (%)

16.7 ± 3.8

Triglyceride (mg/dL)

139 ± 110

Total cholesterol (mg/dL)

169 ± 32

Low-density lipoprotein cholesterol (mg/dL)

94 ± 26

High-density lipoprotein cholesterol (mg/dL)

51 ± 19

Albumin (g/dL)

3.8 ± 0.3

Creatinine (mg/dL)

11.26 ± 3.08

Uric acid (mg/dL)

6.9 ± 1.4

Urea nitrogen (mg/dL)

62.9 ± 13.5

Corrected calcium (mg/dL)

9.0 ± 0.8

Phosphate (mg/dL)

5.7 ± 1.3

C-reactive protein (mg/dL)

0.27 ± 0.79

β2-microglobumin (mg/L)

24.9 ± 5.4

Total carnitine (μmol/L)

44.5 ± 11.7

Free carnitine (μmol/L)

28.6 ± 8.1

Acyl carnitine (μmol/L)

15.9 ± 4.7

Acyl carnitine/free carnitine

0.6 ± 0.1

Skin autofluorescence (arbitrary unit)

3.4 ± 0.7

Left ventricular ejection fraction (%)

66.9 ± 8.9

  1. Data are presented as mean ± standard deviation. Kt/V is used to evaluate the hemodialysis adequacy
  2. ARB angiotensin II receptor blocker, ACE inhibitor angiotensin-converting enzyme inhibitor